Results of Three Polychemotherapy Programs in Non-Hodgkin’s Lymphomas

In the past 10 years, in spite of remark-able therapeutic progress with most hematological malignancies, non-Hodgkin’s lymphoma (NHL) patients, particularly those with unfavorable histological types, remain a crux medicorum. Complete remissions are still comparatively rare and of short duration, and the disease is recurrent and progressive, with little hope of the cure so often observed in Hodgkin’s disease.